Summary of Product Characteristics Updated 13-Oct-2020 | Thea Pharmaceuticals Ltd
Zaditen 0.25 mg/ml, eye drops, solution.
One ml contains 0.345 mg ketotifen fumarate corresponding to 0.25 mg ketotifen.
Each drop contains 8.5 microgram ketotifen fumarate.
Excipient(s) with known effect: Benzalkonium chloride (0.1 mg/ml).
For the full list of excipients, see section 6.1.
Eye drops, solution.
Clear, colourless to faintly yellow solution.
Symptomatic treatment of seasonal allergic conjunctivitis.
Adults, elderly and children (age 3 and older): one drop of Zaditen into the conjunctival sac twice a day.
The safety and efficacy of Zaditen in children aged from birth to 3 years have not yet been established.
Method of administration
The contents and dispenser remain sterile until the original closure is broken. To avoid contamination do not touch any surface with the dropper tip.
Hypersensitivity to the active substance or to any of the excipients listed in Section 6.1.
This medicine contains 2.6 micrograms benzalkonium chloride in each drop.
Benzalkonium chloride may be absorbed by soft contact lenses and may change the colour of the contact lenses. Remove contact lenses prior to application and wait at least 15 minutes before reinsertion.
Benzalkonium chloride may also cause eye irritation, especially in dry eyes or disorders of the cornea.
If Zaditen is used concomitantly with other eye medications there must be an interval of at least 5 minutes between the two medications.
The use of oral dosage forms of ketotifen may potentiate the effect of CNS depressants, antihistamines and alcohol. Although this has not been observed with Zaditen eye drops, the possibility of such effects cannot be excluded.
There are no adequate data from the use of ketotifen eye drops in pregnant women. Animal studies using maternally toxic oral doses showed increased pre- and postnatal mortality, but no teratogenicity. Systemic levels after ocular administration are much lower than after oral use. Caution should be exercised when prescribing to pregnant women.
Although animal data following oral administration show excretion into breast milk, topical administration to human is unlikely to produce detectable quantities in breast milk. Zaditen eye drops can be used during lactation.
There are no data available on the effect of ketotifen fumarate on fertility in humans.
Any patient who experiences blurred vision or somnolence should not drive or operate machines.
Adverse reactions are ranked under heading of frequency, using the following convention: Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data).
Immune system disorders
Nervous system disorders
Common: Eye irritation, eye pain, punctate keratitis, punctate corneal epithelial erosion.
Uncommon: Vision blurred (during instillation), dry eye, eyelid disorder, conjunctivitis, photophobia, conjunctival haemorrhage.
Uncommon: Dry mouth
Skin and subcutaneous tissue disorders
Uncommon: Rash, eczema, urticaria
General disorders and administration site conditions
Adverse drug reactions from post-marketing experience (Frequency not known):
The following post marketing events have also been observed: hypersensitivity reactions including local allergic reaction (mostly contact dermatitis, eye swelling, eyelid pruritis and oedema), systemic allergic reactions including facial swelling/oedema (in some cases associated with contact dermatitis) and exacerbation of pre-existing allergic conditions such as asthma and eczema.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
No case of overdose has been reported.
Oral ingestion of the contents of a 5 ml bottle would be equivalent to 1.25 mg of ketotifen which is 60% of a recommended oral daily dose for a 3 year old child. Clinical results have shown no serious signs or symptoms after oral ingestion of up to 20 mg of ketotifen.
Pharmacotherapeutic group: Ophthalmologicals, other anti-allergics.
ATC code: S01GX08
Ketotifen is a histamine H1-receptor antagonist. In vivo animal studies and in vitro studies suggest the additional activities of mast cell stabilisation and inhibition of infiltration, activation and degranulation of eosinophils.
In a pharmacokinetic study conducted in 18 healthy volunteers with Zaditen eye drops, plasma levels of ketotifen after repeated ocular administration for 14 days were in most cases below the limit of quantitation (20 pg/ml).
After oral administration, ketotifen is eliminated biphasically with an initial half-life of 3 to 5 hours and a terminal half-life of 21 hours. About 1% of the substance is excreted unchanged in the urine within 48 hours and 60 to 70% as metabolites. The main metabolite is the practically inactive ketotifen-N-glucuronide.
Preclinical data reveal no special hazard which is considered relevant in connection with use of Zaditen eye drops in humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction.
Sodium hydroxide (E524)
Water for injections
In unopened bottle: 2 years.
After opening: 4 weeks.
Do not store above 25 °C.
The container is a white-coloured LDPE bottle with a transparent LDPE dropper and a white HDPE screw cap with an integrated safety ring. One bottle contains 5 ml of the solution.
No special requirements.
12, rue Louis-Blériot
63017 Clermont-Ferrand Cedex 2
IC5 Innovation Way, Keele University Science & Innovation Park, Keele, Newcastle Under Lyme, Staffordshire, ST5 5NT, UK
0345 521 1290
0345 521 1290
0345 521 1290